ExperimentalGeneral Remarks. All manipulations were performed in air, except where otherwise noted. The solvents thf and hexane (analytical grade) were freshly distilled from sodium/potassium alloy, dichloromethane was distilled from calcium hydride, the other solvents (acetonitrile, diethylether, acetone) were used as purchased. Deuterated solvents for NMR measurements were distilled from the appropriate drying agents under N 2 immediately prior to use following standard literature methods. 15 Air-sensitive compounds were stored and weighed in a glovebox. The reagents 1,2-dibromoethane, 1,3dibromopropane, 1,4-diiodobutane, 2,6-dimethylaniline, 2,4,6-trimethylaniline, 2,6-diisopropylaniline, triethylorthoformate, sodium tetrafluoroborate, and potassium bis(trimethylsilyl)amide were used as received. 1 H and 13 C NMR spectra were obtained on Bruker Avance AMX 400, 500 or Jeol Eclipse 300 spectrometers. The chemical shifts are given as dimensionless values and are frequency referenced relative to TMS. Coupling constants J are given in hertz (Hz) as positive values regardless of their real individual signs. Abbreviations used: st = septet, br = broad. Mass spectra (MS) and high-resolution mass spectra (HRMS) were obtained in positive electrospray (ES) mode unless otherwise reported, on a Waters Q-TOF micromass spectrometer. 1,3-Bis-(2,4,6-trimethylphenyl)-4,5,6,7-tetrahydro-3H-[1,3]diazepin-1-ium iodide, 7-Mes•HI. The reaction was performed on a 71.0 mmol scale of amidine (19.90 g), 5.00 g of K 2 CO 3 (36.0 mmol) and 22.00 g of 1,4-diiodobutane (71.0 mmol) in 1 L of acetonitrile. The solution was heated under reflux for 5 hours to yield 29.20 g (63.0 mmol, 89%) of white, crystalline material. 1,3-Bis-(2,6-dimethylphenyl)-4,5,6,7-tetrahydro-3H-[1,3]diazepin-1-ium iodide, 7-Xyl•HI. The reaction was performed on a 43.3 mmol scale of amidine (10.93 g), 5.8 mL of 1,4-diiodobutane (13.63 g, 44 mmol), 3.01 g of K 2 CO 3 (22.5 mmol) in 0.5 L of acetonitrile. The solution was heated under reflux for 5 hours to yield 14.85 g (34.2 mmol, 79%) of white, crystalline material. 1,3-Bis-(2,6-diisopropylphenyl)-4,5,6,7-tetrahydro-3H-[1,3]diazepin-1-ium iodide, 7-Pr i •HI. The reaction was performed on a 11.0 mmol scale of amidine (4.00 g), 0.78 g of K 2 CO 3 (5.6 mmol), 1.6 mL of 1,4-diiodobutane (3.76 g, 12.1 mmol) in 400 mL of acetonitrile. The solution was heated under reflux for 17 hours to yield 3.87 g (7.1 mmol, 64%) of white, crystalline material. 2,4-Bis-(2,4,6-trimethylphenyl)-4,5-dihydro-1H-benzo[e][1,3]diazepin-2-ium bromide, Xyl7-Mes•HBr. The reaction was performed on a 35.8 mmol scale of amidine (10.03 g), 36.0 mmol of , 'dibromo-o-xylene (9.49 g), 2.49 g of K 2 CO 3 (18.0 mmol) in 0.5 L of acetonitrile. The solution was heated under reflux for 5 hours to yield 12.42 g (26.2 mmol, 73%) of white, crystalline material. 1 H

No abstract

Poly(ADP-ribose) polymerase (PARP) inhibitors are increasingly being studied as cancer drugs, as single agents, or as a part of combination therapies. Imaging of PARP using a radiolabeled inhibitor has been proposed for patient selection, outcome prediction, dose optimization, genotoxic therapy evaluation, and target engagement imaging of novel PARP-targeting agents. Methods: Here, via the copper-mediated 18 F-radiofluorination of aryl boronic esters, we accessed, for the first time (to our knowledge), the 18 F-radiolabeled isotopolog of the Food and Drug Administration–approved PARP inhibitor olaparib. The use of the 18 F-labeled equivalent of olaparib allows direct prediction of the distribution of olaparib, given its exact structural likeness to the native, nonradiolabeled drug. Results: 18 F-olaparib was taken up selectively in vitro in PARP-1–expressing cells. Irradiation increased PARP-1 expression and 18 F-olaparib uptake in a radiation-dose–dependent fashion. PET imaging in mice showed specific uptake of 18 F-olaparib in tumors expressing PARP-1 (3.2% ± 0.36% of the injected dose per gram of tissue in PSN-1 xenografts), correlating linearly with PARP-1 expression. Two hours after irradiation of the tumor (10 Gy), uptake of 18 F-olaparib increased by 70% ( P = 0.025). Conclusion: Taken together, we show that 18 F-olaparib has great potential for noninvasive tumor imaging and monitoring of radiation damage.

DNA integrity is constantly challenged by endogenous and exogenous factors that can alter the DNA sequence, leading to mutagenesis, aberrant transcriptional activity, and cytotoxicity. Left unrepaired, damaged DNA can ultimately lead to the development of cancer. To overcome this threat, a series of complex mechanisms collectively known as the DNA damage response (DDR) are able to detect the various types of DNA damage that can occur and stimulate the appropriate repair process. Each DNA damage repair pathway leads to the recruitment, upregulation, or activation of specific proteins within the nucleus, which, in some cases, can represent attractive targets for molecular imaging. Given the well-established involvement of DDR during tumorigenesis and cancer therapy, the ability to monitor these repair processes non-invasively using nuclear imaging techniques may facilitate the earlier detection of cancer and may also assist in monitoring response to DNA damaging treatment. This review article aims to provide an overview of recent efforts to develop PET and SPECT radiotracers for imaging of DNA damage repair proteins.

No abstract

The synthesis of the novel ligand tris(2,2¢-bipyrid-6-yl) methanol (L 1 ) is described. Co-ordination of the ligand to the first row transition metals (Mn 2+ -Zn 2+ ) as well as Cd 2+ showed that the ligand formed complexes close to trigonal prismatic in geometry in the solid state. Analysis of the geometry of the co-ordination spheres showed varying degrees of trigonal prismatic and octahedral character. For each d-electron configuration, this could be related to the relative differences in ligand field stabilisation energies for the two geometries.

The elevation of cancer antigen 125 (CA125) levels in the serum of asymptomatic patients precedes the radiologic detection of high-grade serous ovarian cancer by at least 2 mo and the final clinical diagnosis by 5 mo. PET imaging of CA125 expression by ovarian cancer cells may enhance the evaluation of the extent of disease and provide a roadmap to surgery as well as detect recurrence and metastases. Methods 89Zr-labeled mAb-B43.13 was synthesized to target CA125 and evaluated via PET imaging and biodistribution studies in mice bearing OVCAR3 human ovarian adenocarcinoma xenografts. Ex vivo analysis of tumors and lymph nodes was performed via autoradiography, histopathology, and immunohistochemistry. Results PET imaging using 89Zr-DFO-mAb-B43.13 (DFO is desferrioxamine) clearly delineated CA125-positive OVCAR3 xenografts as early as 24 h after the administration of the radioimmunoconjugate. Biodistribution studies revealed accretion of 89Zr-DFO-mAb-B43.13 in the OVCAR3 tumors, ultimately reaching 22.3 ± 6.3 percentage injected dose per gram (%ID/g) at 72 h after injection. Most interestingly, activity concentrations greater than 50 %ID/g were observed in the ipsilateral lymph nodes of the xenograft-bearingmice. Histopathologic analysis of the immuno-PET–positive lymph nodes revealed the presence of grossly metastasized ovarian cancer cells within the lymphoid tissues. In control experiments, only low-level, non-specific uptake of 89Zr-labeled isotype IgG was observed in OVCAR3 tumors; similarly, low-activity concentrations of 89Zr-DFO-mAb-B43.13 accumulated in CA125-negative SKOV3 tumors. Conclusion Immuno-PET with 89Zr-labeled mAb-B43.13 is a potential strategy for the noninvasive delineation of extent of disease and may add value in treatment planning and treatment monitoring of high-grade serous ovarian cancer.

The radiometal (64)Cu is now widely used in the development of diagnostic imaging agents for positron emission tomography (PET). The present study has led to the development and evaluation of a novel chelating agent for (64)Cu: the new monothiourea tripodal ligand 1-benzoyl-3-{6-[(bis-pyridin-2-ylmethyl-amino)-methyl]-pyridin-2-yl}-thiourea (MTUBo). X-ray crystallographic analysis has shown this ligand forms a mononuclear complex with copper(II) and co-ordinates via a trigonal bipyramidal N4S array of donor atoms. Promisingly, cell uptake studies revealed that (64)Cu-MTUBo selectively accumulates in EMT-6 cells incubated under hypoxic conditions which may result from its relatively high Cu(II/I) redox potential. Small-animal PET imaging and ex vivo biodistribution studies in EMT-6 tumor bearing BALB/c mice revealed significant tumor uptake after 1 h p.i., yielding tumor-to-muscle (T/M) and tumor-to-blood (T/B) ratios of 8.1 and 1.1, respectively. However, injection of (64)Cu-acetate resulted in similar uptake indicating that the observed uptake was most likely non-specific. Despite showing high in vitro stability, it is likely that in vivo the complex undergoes transchelation to proteins within the blood in a relatively short timeframe. For comparison, the hypoxia imaging agent (64)Cu-ATSM was also evaluated in the same murine tumor model and showed about 60% higher tumor uptake than (64)Cu-MTUBo.